The Trans Pacific Partnership agreement, labeled a free-trade agreement by some, would actually work to provide large pharmaceutical firms unprecedented advantage against cheaper generic drugs, reducing competition, a POLITICO report concluded. The resulting agreement is by design targeting to enrich the largest pharmaceutical companies, but the unintended consequences could damage the burgeoning U.S. generic pharmaceutical industry. But the TPP’s worst impact could be felt by seniors, who may be practically restricted from accessing life saving treatments. One leaked chapter of the agreement has POLITICO’s head spinning Working off a leaked copy of just one chapter of the agreement, POLITICO reporter Michael Grunwald observed…
- One leaked chapter of the agreement has POLITICO's head spinning
- TPP critics point to the new law restricting free markets to make the playing field uneven
- TPA process actually restricts traditional democratic discussion, as the key points have nothing to do with "free-trade"
- TPP is crushing vibrant and dynamic U.S. business category, restricting free markets in the name of "free-trade"
- Subjugation of U.S. law under TPP, the key whisper issue, comes to light
- The devious key behind TPP: Don't bluntly block U.S. regulatory authority, make it practically impossible
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe now and get 7 days free!
